odm-207
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 22, 2016 (NCT03035591)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- BRD4/HDAC1INHIBITOR
BRD4/HDAC1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2c(cc1-c1c(C)noc1C)cc(C)c(=O)n2Cc1ccccn1- Mol. weight
- 375.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095190 ↗
Also known as
- odm-207
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03035591 | Phase 1/Phase 2 (Phase 2) | Dec 22, 2016 | Orion Corporation, Royal Marsden Hospital NHS Trust |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Orion Corporation | For profit | 1 | 1 | 1 | 2016 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1